Effectiveness and Safety of Ruxolitinib Cream 15 mg/g in Patients With Non‐Segmental Vitiligo: A Real‐Life Study
Eustachio Nettis has a conflict of interest with Sanofi, Abbvie, Leo Pharma, Almirall, Gsk, and Astra-Zeneca. The remaining authors have no conflicts of interest that are directly relevant to the content of this article. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Authors
- Ippolita Zaza
- Andrea D’Amico (ORCID: https://orcid.org/0000-0003-0828-6157)
- Loredana Muolo
- Marco Casciaro (ORCID: https://orcid.org/0000-0002-5436-1501)
- Sebastiano Gangemi (ORCID: https://orcid.org/0000-0001-7001-6532)
- Eustachio Nettis (ORCID: https://orcid.org/0000-0003-1383-105X)
- Francesco Pugliese (ORCID: https://orcid.org/0009-0000-5979-5184)
- Michelina Francesca Daddato
- Mattia Cristallo (ORCID: https://orcid.org/0009-0002-8055-5892)
Institutions
- University of Messina (IT)
- University of Bari Aldo Moro (IT)
Publication Details
- Journal
- International Journal of Dermatology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1111/ijd.70049
- Primary Topic
- melanin and skin pigmentation
- Type
- article
- Field-Weighted Citation Impact
- 0.00